The TeraBioStation is designed as a quick one-stop solution that will transform diagnostic public testing around the world.

In the wake of the COVID-19 pandemic, TERA.Bio was established as a fully owned subsidiary of TERA, focusing solely on the commercialization of its rapid breath mass-screening solution, intended to ‘clear’ healthy populations in their daily activities.

The TERA.Bio Test is ~1-minute clearance test to determine if an individual is Negative to COVID-19 (Clear to Continue). This rapid, non-invasive test uses the sensitivity of Tera Waves to provide accurate and reliable results. Following clinical trials in Israel, Latin America, Asia, USA (pending FDA approval), UAE and Europe (CE Mark approved), TERA.Bio is continuing to grow its number of testing sites.

TERA.Bio Tests analyze breath aerosols and Volatile Organic Compounds (VOC) of viruses, such as COVID-19. In the future, TERA.Bio plans to offer various diagnostic capabilities of SARS-CoV-2 (and its mutations/variations), other viruses, bacteria, and other diseases (cancer, diabetes, etc.)

In real time, the tested individual is notified of their result directly on the TeraBioStation’s display, printed and/or on their smartphone, subject to their consent. Other custom-made solutions can be provided to our clients (for example opening a door/gate if the tested individual result is Clear of COVID-19) upon request.